▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

INmune Bio (NASDAQ: INMB)

$7.72

(-0.6%)

-$0.05

Price as of May 20, 2025, 3:57 p.m. ET

INmune Bio Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
INMB	-28.39%	+27.59%	+4.99%	-3%
S&P	+12.45%	+100.69%	+14.95%	+119%

INmune Bio Company Info

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

News & Analysis

Featured Article

Why INmune Bio Stock Soared Then Sank Today

The wild ride for the biotech stock started with its announcement of results from a phase 1b study.

Keith Speights | Jan 21, 2021

Valuation

Earnings Transcripts

INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript

INMB earnings call for the period ending June 30, 2022.

Motley Fool Transcribing | Aug 4, 2022

INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript

INMB earnings call for the period ending March 31, 2022.

Motley Fool Transcribing | May 6, 2022

INmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript

INMB earnings call for the period ending December 31, 2021.

Motley Fool Transcribing | Mar 4, 2022

INmune Bio, Inc. (INMB) Q3 2021 Earnings Call Transcript

INMB earnings call for the period ending September 30, 2021.

Motley Fool Transcribing | Nov 4, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services